In studies presented this week at the American Academy of
Otolaryngology-Head and Neck Surgery Annual Meeting, researchers found that Coblation-assisted
procedures eliminated the risk of airway fires, and Coblation-Assisted Sinus Surgery (CASS)
procedures lowered the risk of blood loss in nasal polypectomy/endoscopic sinus surgery (ESS).
Results of a study, sponsored by ArthroCare and entitled, Device-Related Risk of Airway Fire in
Oropharyngeal Surgery, presented on the podium by Soham Roy, MD, a member of ArthroCares
Strategic Advisory Board for its ENT division, and Lee Smith, MD, compared the risk of airway fire for
an electrosurgical device (Bovie) and a bipolar radiofrequency ablation wand (Coblator) in a
mechanical chicken cavity model.
Their study found that the risk of airway fire appeared to be eliminated
with Coblation, while electrosurgical devices, such as Bovie, present a significant risk of fire during open
cavity surgery in oxygen-enriched environments. All experimental conditions were tested for four
minutes, or until a positive result was achieved and were repeated in another model to ensure accuracy.
Intraoperative fires are a well-described and devastating complication of oropharyngeal and airway
surgery, some leading to severe injury and/or death, said Dr. Roy, lead investigator of the study from
Childrens ENT of Houston and Texas ENT Consultants. We are currently conducting further
investigations to determine the risk of airway fire with other surgical modalities, including laser, which is
commonly used in ENT procedures.
At the American Rhinologic Society Fall Meeting, conducted in tandem with AAO-HNS, a study, entitled
Effect of Coblation Polypectomy on Estimated Blood Loss in Endoscopic Sinus Surgery (ESS): A Pilot
Study, found that CASS was associated with a statistically significant lower estimated blood loss and
blood loss per minute when compared to traditional microdebridement technique.
Surgical management of refractory chronic rhinosinusitis with nasal polyposis is typically successfully
performed using ESS.1,2 Despite numerous advances in surgical instrumentation and optical aids, intraoperative
hemorrhage remains a major hurtle in ESS with sinonasal polyposis, said Jose W. Ruiz, III,
MD, investigator of the study and assistant professor at the University of Miami, Department of
Otolaryngology. Since adopting Coblation, reduced blood loss and improved surgical visualization have
reduced our concern for complications, including orbital and intracranial injuries. The study concluded
that Coblation represents a viable alternative to microdebridement for patients with nasal polyps
undergoing ESS as it resulted in better visualization as a result of better homeostasis. The study was a
retrospective analysis of 25 patients with nasal polyposis undergoing ESS and was conducted by
investigators Jean Anderson Eloy, MD, Thomas J. Walker, MD, Roy R. Casiano, MD and Jose W. Ruiz,
III, MD.
The Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS)
ran from September 21-24, 2008 at the McCormick Place Convention Center in Chicago, IL.
Sources:
1. Bhattacharyya N. Progress in surgical management of chronic rhinosinusitis and nasal polyposis. Curr Allergy Asthma Rep 7(3):216-220, 2007.
2. Bhattacharyya N. Influence of polyps on outcomes after endoscopic sinus surgery. Laryngoscope 117(10):1834-1838, 2007.
About Arthrocare
Founded in 1993, ArthroCare Corporation is a highly innovative, multi-business
medical device company that develops, manufactures and markets minimally invasive surgical products.
With these products, ArthroCare targets a multi-billion dollar market opportunity across several medical
specialties, significantly improving existing surgical procedures and enabling new, minimally invasive
procedures. Many of ArthroCares products are based on its patented Coblation(R) technology, which
uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue -
minimizing damage to healthy tissue. Used in more than four million surgeries worldwide, Coblation(R)-
based devices have been developed and marketed for sports medicine; spine/neurologic; ear, nose and
throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of
novel technologies to its portfolio, including Opus Medical sports medicine, Parallax spine and Applied
Therapeutics ENT products, to complement Coblation(R) within key indications.
http://www.arthrocare.com
Safe Harbor Statements Cautionary Statement Regarding Forwardlooking
Statements
The information provided in this press release includes forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, including statements regarding the strength or
expected benefits of the Companys technology. Statements that are not historical facts are forward-looking statements. These statements are based on beliefs and assumptions by management, and on information currently available to management.
Forward-looking statements speak only as of the date they are made, and ArthroCare undertakes no
obligation to update any of them publicly in light of new information or future events. A number of
important factors could cause actual results to differ materially from those contained in any forwardlooking
statement. Examples of these factors include, but are not limited to, the strength of the
Companys technology and its continued adoption, unanticipated accounting issues or audit issues
regarding the financial data for the periods being restated in the Companys previously announced
restatement; the ability of the Company and its independent registered public accounting firm to confirm
information or data identified in the review, being overseen by the Audit Committee of the Companys
Board of Directors, of the scope and nature of the Companys internal controls (the
unanticipated issues regarding the Review that prevent or delay the Companys independent registered
public auditing firm from relying upon the Review or that require additional efforts, documentation,
procedures, review or investigation; the Companys ability to design or improve internal controls to
address issues detected in the Review or by management in its reassessment of the Companys internal
controls; the impact upon the Companys operations of the Review, legal compliance matters or internal
controls, improvement and remediation; difficulties in controlling expenses, including costs of the
Review, legal compliance matters or internal controls review, improvement and remediation; the
Companys ability to become current in its SEC periodic reporting requirements; the outcome of pending
litigation; general business, economic and political conditions; competitive developments in the medical
devices market; changes in applicable legislative or regulatory requirements; the Companys ability to
effectively and successfully implement its financial and strategic alternatives, as well as business
strategies, and manage the risks in its business; the reactions of the marketplace to the foregoing; and
other risks and uncertainties discussed more fully in the Companys SEC filings, including those
discussed under Item 1A. Risk Factors in its Form 10-K for the fiscal year ended December 31, 2007.

Similar posts: clinical gynecologic oncology

Similar posts: clinical gynecologic oncology

ORLANDO, FL (UroToday.com) - The authors explored patterns of recurrence, muscle invasion, and disease specific mortality in patients with bladder carcinoma in situ (CIS) who responded to an induction course with intravesical BCG immunotherapy. Between June 1985 and December 2003, 104 patients (mean age of 67 years) were diagnosed with either pure (38 patients) or concomitant (66 patients) CIS.

Similar posts: clinical gynecologic oncology

Americano top 10 >>> clinical gynecologic oncology

All information >>> clinical gynecologic oncology

clinical gynecologic oncology <<< hot news

BOSTON(BUSINESS WIRE)Jun 3, 2008 - The DNA Repair Company (DNAR), an emerging company focused on personalized approaches to cancer treatment, today announced promising early clinical data for identifying effective treatment regimens for head and neck cancer. An analysis of DNA repair protein biomarkers was performed in collaboration with the University of Chicago Medical Center that identified biomarker combinations as novel predictors of response to treatment with induction chemotherapy and overall survival. The data were presented yesterday by the lead investigator Tanguy Seiwert, MD, Department of Medicine, Section of Hematology/Oncology, from The University of Chicago at the 44th Annual American Society for Clinical Oncology Meeting.

All information >>> clinical gynecologic oncology

Americano new top 10 >>> clinical gynecologic oncology

News the best top 10 >>> clinical gynecologic oncology

Top 10 >>> clinical gynecologic oncology

Best sites about >>> clinical gynecologic oncology

All information >>> clinical gynecologic oncology

More info about >>> clinical gynecologic oncology